If the choice is made to anticoagulate patients with symptomatic isolated distal deep vein thrombosis (DVT), outcomes will be improved with 12 versus 6 weeks of treatment, the randomized, ...

Amsterdam, Netherlands – 28 Aug 2023: Twelve months of edoxaban is superior to three months for the reduction of thrombotic events in patients with cancer and distal deep vein thrombosis (DVT), ...

However, optimal anticoagulation strategies for cancer patients with isolated distal DVT are not currently established. ONCO DVT was the first randomized trial to compare two different treatment ...

Anticoagulation is known to prevent further clots developing in patients who have already had a blood clot in their leg, including those with isolated distal deep vein thrombosis (DVT). But doctors ...

Please provide your email address to receive an email when new articles are posted on . Longer vs. shorter-duration anticoagulation reduces thrombotic event risk for patients with cancer and isolated ...

Giving the direct oral anticoagulant (DOAC) edoxaban for 12 months rather than 3 months is better for preventing thrombotic events in patients with active cancer and isolated deep-vein thrombosis (DVT ...

Patients with active cancer and newly diagnosed isolated distal deep vein thrombosis (DVT) who received 12 months of edoxaban (Savaysa) had fewer thrombotic events at 1 year than those who received 3 ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window AMSTERDAM -- A ...

Please provide your email address to receive an email when new articles are posted on . As a coagulationist with a special interest in thrombosis, thrombophilia and anticoagulation, I occasionally ...

If you are diagnosed with a deep vein thrombosis (DVT), a blood clot in one of your deep veins, you may assume that you need to be treated in the hospital. But that’s not always the case. In fact, ...